NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

Epilepsy refers to a group of neurological disorders of varying aetiology, characterized by recurrent brain dysfunction that result from sudden excessive and disordered neuronal discharge. These ...

Vagus Nerve Stimulation therapy is a treatment for epilepsy that involves a stimulator (or 'pulse generator') which is connected, inside the body, to the left vagus nerve in the neck. The stimulator ...

and primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy." The said drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty ...

The total volume of drugs was the most since records began in 1973 There were a total of 217,644 drug seizures made over the period, compared to 191,623 in 2022/23, the data showed. "These ...

Idiopathic acquired anhidrosis has no obvious cause. It is broken down into three types based on where the problem occurs. Idiopathic generalized anhidrosis is considered a type of neuropathy ...

Seizures that impact specific areas of the brain these ways are known as partial seizures - while generalized seizures can affect more than one brain structure at a time or occur throughout the ...

Based on the owner’s, referring veterinarian’s description or hospital records, seizure types were grouped into generalized epileptic seizures only ... μl in one dog with a glioma and RBC 9280 with a ...